drug · small molecule
sepiapterin
Marketedupdated 5mo agoby $PTC PTC INC.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for phenylketonuria and 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying sepiapterin
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 28, 2030
~3.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Mar 6, 2042method-of-use (U-4250)US 12257252
- Mar 6, 2042method-of-use (U-4250)US 12257252
- Sep 4, 2038formulationUS 11752154
- Sep 4, 2038formulationUS 11752154
- Sep 4, 2038method-of-use (U-4251)US 12213982
- Sep 4, 2038method-of-use (U-4251)US 12213982
- Apr 16, 2038compositionUS 11072614
- Apr 16, 2038compositionUS 11072614
FDA exclusivities (2)
- Jul 28, 2030NCENew Chemical Entity (5y)3.8y
- Jul 28, 2030NCENew Chemical Entity (5y)3.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that